The Food and Drug Administration (FDA) approved the first and only drug to treat patients with severe Multiple Sclerosis (MS). The severe condition is Primary Progressive Multiple Sclerosis (PPMS), which is a nervous system disease that harms the brain’s ability to communicate with the rest of the body. The new drug is called Ocrevus and can only be distributed directly into the patient’s veins by a health professional. Clinical trials tested the drug in patients with both MS and PPMS and found it helpful. Although Ocrevus doesn’t prevent PPMS from progressing more, it does slow patients’ worsening symptoms. For those with MS, the drug lowers relapse rates and disability.